peppersite
Peptidesubcutaneous

SS-31

SS-31, also called elamipretide and sold as FORZINITY, is a lab-made peptide of four amino acids that targets mitochondria, the parts of cells that make energy. It has been studied in people with Barth syndrome, heart failure, mitochondrial myopathy and dry age-related macular degeneration.

Researched for
Mitochondria

At a glance

Type
Peptide
Given by
subcutaneous
Evidence
Not yet audited here; the reference library calls it clinical
Reported amount
40 mg per Peptide Dosing Protocols. All 3 sources

How much to draw

Full calculator →
Your draw
–units
Fill in the three numbers to see the draw.
Amount per dose

Opened on 40 mg, the figure Peptide Dosing Protocols reports for SS-31. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.

What sources report

Reference, not a recommendation

These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for SS-31 or for anything else, and nothing below has been checked against the study it came from.

40 mg subcutaneous daily (Phase 3 dose); or 5-10 mg daily (research community range)
Frequency
Once dailyRepeatable
Route
subcutaneous
Reported by
Peptide Protocol Wiki
Standard: 40 mg · Low: 20 mg
Frequency
once daily12 weeks per period Open-label extension All remaining patients on elamipretide 40 mg SC daily Up to 168 weeks Reported in Genetics in Medicine, 2024.
Route
Subcutaneous
Reported by
Peptide Dosing Protocols
What it saysThe standard dosing for SS-31 is 40 mg subcutaneously once daily.
Investigational; commonly studied at 40 mg SC daily - provider-directed
Frequency
once daily (study protocols)Per provider/study protocol · Per provider/study protocol
Route
subcutaneous
Reported by
Commonly published practitioner dosing range - provider confirmation required.
Reconstitution, as reported
  • reconstitution, and safety considerations for this mitochondria-targeted peptide.
  • Compounded; varies · Reconstitute per compounding pharmacy instructions
Not yet audited

We have not published an audit on SS-31. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.

How it is thought to work

SS-31 moves into the inner membrane of the mitochondria and latches onto cardiolipin, a fat molecule that acts as the scaffold holding the energy-making machinery in place. Holding that scaffold steady under stress is the main proposed mechanism. Researchers describe it as stabilizing the cristae and the electron transport chain, which makes it a structural stabilizer rather than a signaling peptide like MOTS-c. In the TAZPOWER trial the randomized 12-week comparison against placebo showed no statistically significant difference on walking distance or fatigue score, with the reported gains coming from the later open-label extension and comparisons against natural-history controls.

In technical termsCardiolipin interaction; mitochondrial function support.

What we don't know

Strength of the Barth syndrome result: in the randomized part of the TAZPOWER trial, the week 12 measures showed no statistically significant difference from placebo. The later improvements were reported in an open-label extension, some of them against natural-history controls.

Other diseases: trials in heart failure, primary mitochondrial myopathy and dry age-related macular degeneration had not led to an FDA approval as of June 2026. Our audit describes those clinical signals as variable and still needing confirmation on hard clinical endpoints.

Healthy adults: no published human trial covers anti-aging, athletic performance or healthy adult use. Safety beyond roughly 3.5 years, the longest follow-up, is not established in healthy adults.

Dialysis, pregnancy and breastfeeding: the label says data are insufficient for adults on dialysis. Data in pregnancy and lactation are limited.

Reported side effects

Seen in studies: reactions where the injection was given, including redness, swelling, itching or mild pain, were the most common adverse events in TAZPOWER and its long-term extension. Headache was reported, especially in the first weeks, along with dizziness, mild nausea or fatigue that mostly settled on their own.

Not ruled out: the Forzinity label notes that serious hypersensitivity reactions have been seen and lists hypersensitivity to any ingredient as a contraindication. The product contains benzyl alcohol and is not for use in newborns, because benzyl alcohol has caused metabolic acidosis and gasping syndrome. Elamipretide and its inactive breakdown products build up in severe kidney impairment, and the label sets a lower daily amount for adults with reduced kidney function who are not on dialysis. No significant drug interactions have been identified, though medicines that stress the kidneys are flagged for clinician attention. Research-use vials are made outside FDA manufacturing oversight, so purity, identity and endotoxin content vary by supplier and lot, and safety beyond roughly 3.5 years, the longest follow-up, is not established in healthy adults.

Who should avoid it

People with serious hypersensitivity to elamipretide or any ingredient: listed as a contraindication on the label.

Newborns: the vial contains benzyl alcohol, which has caused serious reactions in low-birth-weight and preterm newborns.

Adults with severe kidney impairment not on dialysis: the drug and its inactive breakdown products accumulate, and the label sets a reduced daily amount for this group.

Adults with severe kidney impairment on dialysis: the label reports insufficient data and gives no recommended regimen.

People who are pregnant or breastfeeding: data are limited, and the label refers these decisions to the prescriber.

Healthy adults seeking anti-aging, cognitive or athletic benefits: no published human trial establishes any amount or benefit for this group.

People with mitochondrial myopathy, heart failure or dry age-related macular degeneration: these have been studied, but as of June 2026 none has led to approval and the work remains investigational.

People weighing under 30 kg: outside the approved population.

Regulatory status

FDA approval: elamipretide, sold as Forzinity, received accelerated FDA approval on September 19, 2025. The approval is for improving muscle strength in adult and pediatric patients with Barth syndrome who weigh at least 30 kg. It is a prescription drug marketed by Stealth BioTherapeutics.

Other uses: it is not approved for any other use. As of June 2026, trials in heart failure, primary mitochondrial myopathy and dry age-related macular degeneration had not produced an FDA approval, and that work remained investigational.

Research vials: vials sold for research use are made outside FDA manufacturing oversight, so purity, identity and endotoxin content vary by supplier and lot.

Checked: November 2026.

Common questions

Is SS-31 the same as elamipretide and Forzinity?

Yes. SS-31 is the original research code, elamipretide is the generic drug name, and FORZINITY is the FDA-approved brand name. Earlier development codes were MTP-131 and Bendavia.

Is SS-31 FDA-approved?

Partly. It received accelerated FDA approval on 19 September 2025 for improving muscle strength in adults and children with Barth syndrome who weigh at least 30 kg. It is not approved for any other use.

What amount was used in the SS-31 clinical trial?

The TAZPOWER trial used 40 mg under the skin once daily. That figure comes from the trial protocol in a tightly defined Barth syndrome population.

Does SS-31 need to be reconstituted?

Forzinity, the approved product, does not require reconstitution. Research-use vials typically do, and those are made outside FDA manufacturing oversight.

How long is a typical SS-31 cycle?

There is no endorsed personal-use cycle. The Forzinity label describes continuous daily dosing, and the longest trial follow-up ran to about week 168.

What are the most common SS-31 side effects?

Reactions at the injection site were the most common in trials, followed by headache, mild nausea and fatigue. Most were self-limited.

Who should avoid SS-31?

The label rules out anyone with serious hypersensitivity to elamipretide or its other ingredients, and newborns because the vial contains benzyl alcohol. People with severe kidney impairment and those who are pregnant or breastfeeding are flagged for clinician oversight.

How does SS-31 compare to MOTS-c?

They work in different ways: SS-31 sits in the mitochondrial membrane and stabilizes its structure, while MOTS-c is a signaling peptide that changes how cells regulate energy metabolism. Their evidence bases differ too, with MOTS-c having only preclinical and small human studies and no approval.

Sources

The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.